BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Nitto Denko Corp.

Headquarters: Osaka, Japan
Year Founded: 1918
Status: Public
Industry Sector: ElectronicTechnology
CEO: Hideo Takasaki
Number Of Employees: 25,300
Enterprise Value: $10,943,891,242
PE Ratio: 14.26
Exchange/Ticker 1: Tokyo:6988
Exchange/Ticker 2: N/A
Latest Market Cap: $12,872,360,305

BioCentury | Nov 19, 2016
Strategy

Adding on in fibrosis

Why Bristol-Myers licensed Nitto Denko’s antifibrotic Hsp47 therapy
BioCentury | Nov 11, 2016
Company News

Nitto, Bristol-Myers deal

BioCentury | Dec 7, 2015
Clinical News

ND-L02-s0201 regulatory update

BioCentury | Sep 23, 2013
Company News

Astellas, Toa Eiyo sales and marketing update

BioCentury | Jul 15, 2013
Clinical News

Bisono Tape regulatory update

BioCentury | Feb 14, 2011
Company News

Avecia, Nitto Denko deal

BioCentury | Jul 26, 2010
Company News

Nitto Denko, Quark deal

BioCentury | Nov 14, 2005
Company News

BioDelivery, Nitto Denko deal

Items per page:
1 - 10 of 13